Molecular characterisation of the first New Delhi metallo-β-lactamase 1-producing Acinetobacter baumannii from Tanzania
Moyo, Sabrina John; Manyahi, Joel; Hubbard, Alasdair T. M; Byrne, Rachel L; Masoud, Nahya Salim; Aboud, Said; Manji, Karim; Blomberg, Bjørn; Langeland, Nina; Roberts, Adam P.
Journal article, Peer reviewed
Published version
View/ Open
Date
2021Metadata
Show full item recordCollections
- Department of Clinical Science [2395]
- Registrations from Cristin [10399]
Original version
Transactions of the Royal Society of Tropical Medicine and Hygiene. 2021, 115 (9), 1080-1085. 10.1093/trstmh/traa173Abstract
Background
We aimed to characterise the genetic determinants and context of two meropenem-resistant clinical isolates of Acinetobacter baumannii isolated from children hospitalised with bloodstream infections in Dar es Salaam, Tanzania.
Methods
Antimicrobial susceptibility was determined by disc diffusion E-test and broth microdilution. Genomes were completed using a hybrid assembly of Illumina and Oxford Nanopore Technologies sequencing reads and characterisation of the genetic context of resistance genes, multi-locus sequence types (STs) and phylogenetic analysis was determined bioinformatically.
Results
Twelve A. baumannii were isolated from 2226 blood cultures, two of which were meropenem-resistant. The two meropenem-resistant isolates, belonging to distinct STs, ST374 and ST239, were found to harbour blaNDM-1, which was chromosomally located in isolate DT0544 and plasmid-located in isolate DT01139. The genetic environment of blaNDM-1 shows the association of insertion sequence ISAba125 with blaNDM-1 in both isolates. Both isolates also harboured genes conferring resistance to other β-lactams, aminoglycosides and cotrimoxazole.
Conclusions
This is the first report of New Delhi metallo-β-lactamase-producing isolates of A. baumannii from Tanzania. The genetic context of blaNDM-1 provides further evidence of the importance of ISAba125 in the spread of blaNDM-1 in A. baumannii. Local surveillance should be strengthened to keep clinicians updated on the incidence of these and other multidrug-resistant and difficult-to-treat bacteria.